ATE114673T1 - Modulator der anabolischen aktivität und seine verwendungen. - Google Patents

Modulator der anabolischen aktivität und seine verwendungen.

Info

Publication number
ATE114673T1
ATE114673T1 AT86110967T AT86110967T ATE114673T1 AT E114673 T1 ATE114673 T1 AT E114673T1 AT 86110967 T AT86110967 T AT 86110967T AT 86110967 T AT86110967 T AT 86110967T AT E114673 T1 ATE114673 T1 AT E114673T1
Authority
AT
Austria
Prior art keywords
anabolic activity
activity modulator
cachectin
disclosed
test
Prior art date
Application number
AT86110967T
Other languages
English (en)
Inventor
Anthony Cerami
Masanobu Kawakami
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25077710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE114673(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE114673T1 publication Critical patent/ATE114673T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Stereo-Broadcasting Methods (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubrication Of Internal Combustion Engines (AREA)
AT86110967T 1985-08-16 1986-08-08 Modulator der anabolischen aktivität und seine verwendungen. ATE114673T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76685285A 1985-08-16 1985-08-16

Publications (1)

Publication Number Publication Date
ATE114673T1 true ATE114673T1 (de) 1994-12-15

Family

ID=25077710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86110967T ATE114673T1 (de) 1985-08-16 1986-08-08 Modulator der anabolischen aktivität und seine verwendungen.

Country Status (5)

Country Link
EP (2) EP0212489B1 (de)
JP (1) JP2506340B2 (de)
AT (1) ATE114673T1 (de)
AU (2) AU6151186A (de)
DE (1) DE3650150T2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419927B1 (en) 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US6309640B1 (en) 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
WO1992006196A1 (en) * 1990-09-28 1992-04-16 Cetus Oncology Corporation Gro genes, proteins, and uses thereof
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
FR2699283B1 (fr) * 1992-12-15 1995-03-03 Medgenix Diagnostic Test de pyrogénicite et kit de mise en Óoeuvre.
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
CA2264200A1 (en) * 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Human endokine alpha
US5998171A (en) 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
DK0939804T4 (da) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
EP2738179A1 (de) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antikörperreinigung
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
EP2249809A1 (de) 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Pulverförmige protein-zusammensetzungen und herstellungsverfahren
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (de) 2013-10-04 2016-08-10 AbbVie Inc. Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
EP3579871A4 (de) 2017-02-07 2021-07-21 Janssen Biotech, Inc. Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktivem morbus bechterew
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US414098A (en) * 1889-10-29 Otto westphal
CA1208546A (en) * 1981-09-08 1986-07-29 Anthony Cerami Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator

Also Published As

Publication number Publication date
DE3650150D1 (de) 1995-01-12
EP0212489A3 (en) 1989-04-26
AU6151186A (en) 1987-02-19
EP0212489A2 (de) 1987-03-04
DE3650150T2 (de) 1995-04-27
EP0613006A1 (de) 1994-08-31
JP2506340B2 (ja) 1996-06-12
EP0212489B1 (de) 1994-11-30
JPS62116599A (ja) 1987-05-28
AU649019B2 (en) 1994-05-12
AU7262691A (en) 1991-05-30

Similar Documents

Publication Publication Date Title
DE3650150D1 (de) Modulator der anabolischen Aktivität und seine Verwendungen.
LV10538A (lv) Imunologiski saistamas vielas noteiksanas panemiens biologiska skidruma un diagnostikas lidzeklis
DK571287A (da) Apparat til automatiseret patientproeveanalyse
DE3670910D1 (de) Gleichzeitige nmr-analyse mehrfacher proben.
ATE77488T1 (de) In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
ES8302311A1 (es) Metodo para la determinacion de un analito biologico de interes utilizando agentes pluorescentes encapsulados.
FI915150A7 (fi) Menetelmät, reagenssit ja testikäyttöpakkaukset biologisten yksiköiden alapopulaatioiden määrittämiseksi
FI895959A7 (fi) Koostumus, diagnostinen käyttöpakkaus ja menetelmä vasta-aineiden nope aksi toteamiseksi
DE3751169D1 (de) Zusammensetzungen und Verfahren zur Synthese und Analyse von Enkephalinase.
EP0101681A4 (de) Antikörper gegen eine Zusammensetzung mit Mediatoraktivität und seine Verwendung in einer pharmazeutischen Zusammensetzung.
DE3650219D1 (de) Verwendung von nichtradioaktiv gekennzeichnete Mikrokügelchen zur Blutströmungsmessung.
DK0434319T3 (da) Fremgangsmåde til afprøvning af virkningen af et stof på hårvækst
NO172708C (no) Fremgangsmaate for omdannelse av stabilt glucohemoglobin til glucitollysin-hemoglobin, mengdebestemmelse av stabilt glucohemoglobin, samt diagnostisk system for utfoerelse av mengdebestemmelsen
ATE77700T1 (de) Immunkomplextestverfahren.
KR880701885A (ko) 2개의 표식물을 이용한 분석물질의 농도 검정 방법 및 기기
DE69128181D1 (de) Enzymtests
JPS5292773A (en) Automatic analyzer
ES8601309A1 (es) Un metodo de medir un ligando biologico
DE3767659D1 (de) Verfahren und testelement zum auffinden von zellaesionen.
FI861321A0 (fi) Foerfaranden foer stabilisering av prostatspecifik antigen i naturella matriser.
DK563588D0 (da) Proevningsapparat til brug ved proevning for en analysand
DK0398621T3 (da) Immunoassay for elastase-1
JPS51144293A (en) Continuous analysis system of urine, etc
DE68917732D1 (de) Immuntestverfahren von chondrocalcin.
JPS52151784A (en) Means for chemical or biological analysis and identifying method of microorganism by said means

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked